

Supplemental Online Content

Mariados NF, Orio III PF, Schiffman Z, et al. Hyaluronic acid spacer for hypofractionated prostate radiation therapy: a randomized clinical trial. *JAMA Oncol*. Published online February 9, 2023. doi:10.1001/jamaoncol.2022.7592

eFigure. T2-weighted MRI of a patient injected with HA spacer

eTable 1. Enrollment by site for randomized patients


eTable 2. Ease of Use for placing HA spacer for spacer group

eTable 3. Dose-volume histogram data of bladder dose before and after spacer injection for spacer group

eTable 4. Dose-volume histogram data of penile bulb dose before and after spacer injection for spacer group

eTable 5. Comparison of dose-volume histogram metrics between control and spacer groups

This supplemental material has been provided by the authors to give readers additional information about their work.



eFigure: T2-weighted MRI of a patient injected with HA spacer.

eTable 1: Enrollment by site for randomized patients.

Principal Investigator	Affiliation	Spacer (n=136)	Control (n=65)
Thomas Boike, MD & Alvaro Martinez, MD	Genesis Care	9 (6.7 %)	5 (7.7 %)
Gregory Bell, MD & Douglas Rivera, MD	Austin Cancer Center	2 (1.5 %)	0 (0.0%)
Michael Chao, MD	Ringwood Private Hospital	12 (8.9 %)	5 (7.7 %)
Alexander Engelman, MD	Florida Urology Partners	21 (15.6 %)	10 (15.4 %)
Glen Gejerman, MD	New Jersey Urology	3 (2.2 %)	4 (6.2 %)
Martin King, MD	Dana Farber Cancer Institute	1 (0.7 %)	0 (0.0%)
John Lederer, MD	The Cancer Center of Hawaii	3 (2.2 %)	3 (4.6 %)
Escarlata Lopez, MD	Vithas La Milagrosa Hospital	15 (11.1 %)	5 (7.7 %)
Neil Mariados, MD	Associated Medical Professional of NY	20 (14.8 %)	11 (16.9 %)
Rizwan Nurani, MD & Steven Kurtzman, MD	Western Radiology Oncology	14 (10.4 %)	9 (13.8 %)
Zvi Schiffman, MD & Thanh John Van	Houston Metro Urology	30 (22.2 %)	12 (18.5 %)
John Sylvester, MD	21st Century Oncology	5 (3.7 %)	1 (1.5 %)

eTable 2: Ease of Use for placing HA spacer for spacer group.

Parameter	N (%)
Very Easy	45 (33.1)
Easy	81 (59.6)
Difficult	9 (6.6)
Very Difficult	1 (0.7)

eTable 3: Dose-volume histogram data of bladder dose before and after spacer injection for spacer group.

Parameter	Statistic	V60	V48.6	V40.8
Baseline (%)	Mean (SD) Range	5.6 (3.1) (0, 17)	11.7 (6.3) (0, 32)	16.2 (8.7) (0, 46)
Post-spacer Injection (%)	Mean (SD) Range	4.9 (2.5) (1, 10)	10.5 (5.1) (2, 24)	14.5 (6.9) (3, 34)

eTable 4: Dose-volume histogram data of penile bulb dose before and after spacer injection for spacer group.

Parameter	Statistic	V57	V40.8
Baseline (%)	Mean (SD) Range	1.7 (6.2) (0, 57)	11.4 (13.4) (0, 82)
Post-spacer Injection (%)	Mean (SD) Range	1.8 (6.7) (0, 64)	9.6 (14.4) (0, 97)

eTable 5: Comparison of dose-volume histogram metrics between control and spacer groups.

Parameter (%)	Spacer	Control
Rectum V57	0.9 (1.5) (0, 10)	7.0 (3.7) (0, 14)
Rectum V54	1.5 (2.3) (0, 18)	9.1 (4.5) (0, 18)
Rectum V53	1.7 (2.6) (0, 21)	9.8 (4.7) (1, 19)
Rectum V49	2.9 (3.9) (0, 33)	12.2 (5.6) (1, 23)
Rectum V45	4.3 (5.4) (0, 48)	14.6 (6.5) (2, 28)
Rectum V38	8.0 (8.9) (0, 82)	19.2 (8.2) (3, 41)
Bladder V60	4.9 (2.5) (1, 10)	4.9 (3.1) (0, 14)
Bladder V48.6	10.5 (5.1) (2, 24)	10.7 (6.5) (0, 25)
Bladder V40.8	14.5 (6.9) (3, 34)	15.2 (9.0) (0, 36)
Penile bulb V57	1.8 (6.7) (0, 64)	1.8 (4.1) (0, 15)
Penile bulb V40.8	9.6 (14.4) (0, 97)	9.8 (13.2) (0, 42)